The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2019 | FLAURA final analysis: osimertinib for first-line EGFRm NSCLC
Suresh Ramalingam, MD, FASCO, of Winship Cancer Institute, Emory University, Atlanta, GA, discusses the final overall survival analysis of the FLAURA trial (NCT02296125) at the European Society for Medical Oncology (ESMO) congress 2019 in Barcelona, Spain. The study compared osimertinib to comparator EGFR-TKI as a first-line treatment for EGFR mutated advanced non-small cell lung cancer, and found the median progression-free survival to be significantly longer with osimertinib. Following this, Pilar Garrido, MD, PhD, from the University of Alcalá, Madrid, Spain, gives her thoughts on the results.
